NVX-207 (C007B-378844)

NVX-207, a Betulinic acid-derived anti-cancer compound, shows anti-tumor activity (mean IC 50 =3.5 μM) against various human and canine cell lines. NVX-207-induced apoptosis is associated with activation of the intrinsic apoptotic pathway via cleavage of caspases -9, -3, -7 and of PARP.In VitroNVX-207 induces cell death via apoptosis. NVX-207 has a high cytotoxicity with IC 50 values ranging from 7.6-8.5 µM, in the three analyzed malignant glioma cell lines. NVX-207 leads to PARP cleavage and to a decrease in Survivin expression levels under normoxic and hypoxic conditions. NVX-207 (20 µM) causes a significantly high rate of necrosis of glioma cell lines. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoIntravenous application of NVX-207 in mice is well tolerated . MCE has not independently confirmed the accuracy of these methods. They are for reference only.Cell AssayCytotoxic activities are evaluated using the Sulforhodamine-B (SRB) assay. Exponentially growing cells are seeded into 96-well plates at cell densities to prevent confluence for 96 h. After 24 h, the cells are treated using a dilution series of the compounds for 72 h under normoxic or hypoxic conditions. After treatment, the adherent cells are fixed using 10% TCA at 4°C for 1 h; the cells are washed with ice-cold water and are dyed using 100 µL of 4.4% SRB solution for 10 min. After staining, the plates are washed with 1% acetic acid and air-dried overnight. Three hundred microliters of 20 mM Tris base solution is added, and the absorbance is measured at 540 nm using a 96-well plate reader. The IC 50 values indicate the concentrations of the compound that cause 50% cell inhibition. The data are obtained in three independent experiments. MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:Solid. Specification: ≥98.0% Molecular Formula: C36H59NO6 Molecular Weight: 601.86 PubChem CID: 9960374 Isomeric SMILES: CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)OC(=O)C)C)C(=O)OCC(CO)(CO)N